Dr. Reddy's CDMO Arm Aurigene Signs Long-Term Global Pharma Deal
Add Preferred News Source
Dr. Reddy's Laboratories subsidiary Aurigene Pharmaceutical Services has signed a long-term manufacturing and supply agreement covering more than 20 products, with commercial supplies expected from 2028.
Aurigene Pharmaceutical Services, the contract research, development and manufacturing (CDMO) arm of Dr. Reddy’s Laboratories, has entered into a long-term manufacturing and supply agreement with a global pharmaceutical company. The name of the partner has not been disclosed.
The deal covers sterile injectables, biologics and topical formulations for markets in the US, Europe, Canada and emerging markets. The products will be made at Aurigene’s facilities in India, with commercial manufacturing expected to begin after a phased technology-transfer programme.
What Does The Aurigene Manufacturing Deal Cover?
The initial portfolio includes more than 20 products across three categories, including sterile injectables, biologics and topical formulations.
Aurigene will handle the programme from technology transfer and process development through scale-up, validation and commercial manufacturing. Long-term supply will follow once the products move through the required stages.
The technology-transfer process is expected to take two to three years. Revenue from the agreement is expected to start contributing in the calendar year 2028. At full commercialisation, the portfolio is expected to generate annual volumes of around 18 million units. Injectables will account for most of these volumes.
The global pharmaceutical company has not been named because of confidentiality obligations.
How Will The Partnership Expand Aurigene’s Drug-Product Business?
The agreement establishes an end-to-end manufacturing framework covering the movement of products from technical transfer to commercial supply. Aurigene said the arrangement is expected to support the scale-up of its drug-product business.
Aurigene Pharmaceutical Services CEO Akhil Ravi said the collaboration reflects the confidence placed by global innovators in the company's integrated drug-product development and manufacturing capabilities.
He also said the partnership would provide long-term revenue visibility and support the company's focus on reliable, high-quality supply to patients across markets.
The programme will therefore move in stages rather than into full commercial production immediately. Technology transfer, development, scale-up and validation will precede the planned supply phase.
Dr. Reddy’s Share Price
Dr. Reddy's share price closed at ₹1,193.50 on 25 August 2026. The stock was up ₹3.50, or 0.29%.
The agreement adds a long-term manufacturing programme to the business activities of Dr. Reddy's Laboratories, through its Aurigene subsidiary. The deal covers markets across North America, Europe and emerging economies, with revenue contribution from the new programme scheduled to begin in 2028.
Also Read - Stocks To Watch Today
This article is for informational purposes only and should not be considered investment advice from Kotak Neo. For compliance T&C and disclaimers, Visit www.kotakneo.com/disclaimer
Vishwa has spent 10+ years across fintech and FMCG doing what most people miss, connecting the dots, catching trends before they trend, and finding the angle nobody else thought to ask about.
At Kotak Neo, she drives content strategy for neoshorts, Kotak News Desk, and Investing Guide, turning market noise into something worth reading.
When she's not decoding markets, she trades charts for canvases, chasing art, painting, and architecture across cities she's yet to explore.
Right Tools, Rich Insights
